创新药，大消息！刚刚，国家医保局宣布

Core Viewpoint - The first version of the commercial insurance innovative drug directory is set to be officially released on the first weekend of December, with the aim of promoting the accessibility of innovative drugs in China [2][4]. Group 1: Drug Directory Negotiations - From October 30 to November 3, the National Healthcare Security Administration (NHSA) organized negotiations for the 2025 National Basic Medical Insurance Drug Directory and price negotiations for the commercial insurance innovative drug directory, involving 120 domestic and foreign enterprises [4]. - A total of 127 drugs not included in the basic medical insurance drug directory and 24 drugs for the commercial insurance innovative drug directory participated in the negotiations [4]. Group 2: Policy Support for Innovative Drugs - The NHSA and the National Health Commission previously released measures to support the high-quality development of innovative drugs, with a focus on establishing the commercial insurance innovative drug directory [4]. - The NHSA aims to ensure a stable outlet for commercial insurance innovative drugs and improve drug accessibility through the integration of the medical insurance drug directory and the commercial insurance innovative drug directory [4]. Group 3: Current Payment Structure for Innovative Drugs - In 2023, the payment structure for innovative drugs in China shows that personal payments account for 49%, basic medical insurance for 44%, and commercial health insurance for only 7% [5].